<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239238</url>
  </required_header>
  <id_info>
    <org_study_id>10-2-064</org_study_id>
    <nct_id>NCT01239238</nct_id>
  </id_info>
  <brief_title>Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study</brief_title>
  <acronym>RASTER</acronym>
  <official_title>Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present proposal was to investigate the predictive properties of markers
      in exhaled breath to predict an asthma exacerbation. In addition, the reliability of home
      monitor assessments to measure asthma control will be examined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>increase of asthma symptoms, use of short b2-agonists, drop in FEV1% of maximum personal value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>asthma control</measure>
    <time_frame>1 year</time_frame>
    <description>asthma control questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Asthma Quality of Life questionnaire for children</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness</measure>
    <time_frame>1 year</time_frame>
    <description>incremental cost per exacerbation prevented</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">102</enrollment>
  <condition>Asthma</condition>
  <condition>Children</condition>
  <condition>Home Monitoring</condition>
  <condition>Exhaled Breath Condensate</condition>
  <condition>Non-invasive Inflammatory Markers</condition>
  <condition>Volatile Organic Compounds</condition>
  <arm_group>
    <arm_group_label>Care as usual</arm_group_label>
    <description>Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study is carried out in two hospitals in the Netherlands (Maastricht University
        Medical Centre, Maastricht; and Orbis Medical Centre, Sittard).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. already known with a diagnosis of asthma during at least 6 months

          2. age between 6 and 17 years

          3. reversibility to a bronchodilator (increase in FEV1 &gt; 9% of predicted value and/or

          4. bronchial hyperresponsiveness to histamine &lt; 8 mg/ml.

        Exclusion Criteria:

          1. cardiac abnormalities

          2. mental retardation, congenital abnormalities or existence of a syndrome

          3. active smoking

          4. no technical satisfactory performance of measurements

          5. no phone line or internet assess available at home.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Dompeling, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Hospital</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orbis Medical Centre</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>children</keyword>
  <keyword>home monitoring</keyword>
  <keyword>exhaled breath condensate</keyword>
  <keyword>non-invasive inflammatory markers</keyword>
  <keyword>volatile organic compounds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

